摘要
目的对治疗原发性中重度高血压的三组方案进行药物经济学评价。方法:选择45例中重度原发性高血压患者,随机分成3组,每组各15例。非洛地平组:单用非洛地平5mg,qd;非洛地平与氯沙坦合用组:非洛地平5mg,qd,加氯沙坦50mg,qd;非洛地平与海捷亚合用组:非洛地平5mg,qd,加海捷亚50mg,qd;3组疗程均为12周,观察3组治疗疗效。结果与结论:三组治疗方案中,非洛地平联合海捷亚组疗效高且更为经济。
Objective To evaluate three schemes of medium and severe idiopathic hypertension treatment. Methods Forty five cases with medium and severe idiopathic hypertension were randomly and averagely assigned to three groups as follows, Felodipine group, Felodipine and Losartan combination group, Felodipine and Hyzaar combination group. The first group only used felodipine 5 mg once daily, the second group used Felodipine 5 mg and Losartan 50 mg once daily, and the third group used Felodipin 5 mg and Hyzaar 50 mg once daily. The course of treatment for all three groups had last out 12 weeks. Results and Conclusion Felodipine and Hyzaar combination group showed higher therapeutic effect and less economic cost.
出处
《药品评价》
CAS
2006年第4期286-288,共3页
Drug Evaluation
关键词
高血压
药物经济学
成本效果分析法
敏感度分析
hypertension
Pharraacoeconomics
cost-effectiveness analysis
sensitivity analysis.
